Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SABGlobeNewsWire · 3 days ago
Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM TherapyGlobeNewsWire · Oct 1, 2026
OBIO's Capital Access Advisory Program (CAAP®) Reaches Milestone with $1 Billion Raised by High-Growth Life Sciences and Health Tech VenturesBusiness Wire · Sep 29, 2026
Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?Zacks Investment Research · Sep 21, 2026
Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026GlobeNewsWire · Sep 16, 2026
Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by HaemoneticsGlobeNewsWire · Sep 15, 2026Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 10, 2026 | -$0.39 | -$0.38 | Beat |
| May 12, 2026 | -$0.40 | -$0.33 | Beat |
| Mar 12, 2026 | -$0.38 | $0.12 | Beat |
| Nov 10, 2025 | -$0.38 | -$0.40 | Miss |
| Aug 12, 2025 | -$0.51 | -$0.50 | Beat |
| Apr 2, 2025 | -$0.43 | -$0.43 | Beat |